- Home
- GHY vs ARCT Comparison
GHY vs ARCT Comparison
Compare GHY & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHY
- ARCT
- Stock Information
- Founded
- GHY 2012
- ARCT 2013
- Country
- GHY United States
- ARCT United States
- Employees
- GHY N/A
- ARCT N/A
- Industry
- GHY Trusts Except Educational Religious and Charitable
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- GHY Finance
- ARCT Health Care
- Exchange
- GHY Nasdaq
- ARCT Nasdaq
- Market Cap
- GHY 494.8M
- ARCT 444.5M
- IPO Year
- GHY N/A
- ARCT N/A
- Fundamental
- Price
- GHY $12.03
- ARCT $10.53
- Analyst Decision
- GHY
- ARCT Strong Buy
- Analyst Count
- GHY 0
- ARCT 7
- Target Price
- GHY N/A
- ARCT $57.80
- AVG Volume (30 Days)
- GHY 184.8K
- ARCT 462.9K
- Earning Date
- GHY 01-01-0001
- ARCT 05-07-2025
- Dividend Yield
- GHY 10.58%
- ARCT N/A
- EPS Growth
- GHY N/A
- ARCT N/A
- EPS
- GHY N/A
- ARCT N/A
- Revenue
- GHY N/A
- ARCT $152,310,000.00
- Revenue This Year
- GHY N/A
- ARCT N/A
- Revenue Next Year
- GHY N/A
- ARCT $39.21
- P/E Ratio
- GHY N/A
- ARCT N/A
- Revenue Growth
- GHY N/A
- ARCT N/A
- 52 Week Low
- GHY $10.24
- ARCT $8.04
- 52 Week High
- GHY $11.92
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- GHY 40.21
- ARCT 43.14
- Support Level
- GHY $11.31
- ARCT $10.07
- Resistance Level
- GHY $12.02
- ARCT $11.00
- Average True Range (ATR)
- GHY 0.38
- ARCT 0.88
- MACD
- GHY -0.06
- ARCT 0.26
- Stochastic Oscillator
- GHY 32.73
- ARCT 77.81
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.